{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=H1+receptor+antagonist&page=2", "query": { "intervention": "H1 receptor antagonist", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 99, "total_pages": 10, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=H1+receptor+antagonist&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=H1+receptor+antagonist&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T17:09:40.220Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06780111", "title": "Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Esophageal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "I-DXd", "type": "BIOLOGICAL" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Levoleucovorin", "type": "DRUG" }, { "name": "5-Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Sacituzumab tirumotecan", "type": "BIOLOGICAL" }, { "name": "Rescue Medication", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 298, "start_date": "2025-07-30", "completion_date": "2032-01-04", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-06T17:09:40.220Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06780111" }, { "nct_id": "NCT07358364", "title": "Remibrutinib in Real-world Clinical Practice", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Spontaneous Urticaria" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3280, "start_date": "2026-02-02", "completion_date": "2031-10-30", "has_results": false, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-10-06T17:09:40.220Z", "location_count": 1, "location_summary": "Kirksville, Missouri", "locations": [ { "city": "Kirksville", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07358364" }, { "nct_id": "NCT05574504", "title": "Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Cancer", "Urothelial Carcinoma" ], "interventions": [ { "name": "avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AdventHealth", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2023-05-08", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2024-08-01", "last_synced_at": "2026-10-06T17:09:40.220Z", "location_count": 1, "location_summary": "Orlando, Florida", "locations": [ { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05574504" }, { "nct_id": "NCT04681729", "title": "Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cold Urticaria" ], "interventions": [ { "name": "Dupilumab SAR231893", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Non sedating H1-antihistamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "12 Years to 80 Years" }, "enrollment_count": 82, "start_date": "2020-12-10", "completion_date": "2023-04-20", "has_results": true, "last_update_posted_date": "2025-09-10", "last_synced_at": "2026-10-06T17:09:40.220Z", "location_count": 5, "location_summary": "San Diego, California • Boise, Idaho • Owensboro, Kentucky + 2 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Boise", "state": "Idaho" }, { "city": "Owensboro", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04681729" }, { "nct_id": "NCT05528861", "title": "A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Spontaneous Urticaria" ], "interventions": [ { "name": "Lirentelimab (AK002)", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Allakos Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 127, "start_date": "2022-10-26", "completion_date": "2024-04-18", "has_results": true, "last_update_posted_date": "2024-09-27", "last_synced_at": "2026-10-06T17:09:40.220Z", "location_count": 51, "location_summary": "Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 44 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Cullman", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05528861" }, { "nct_id": "NCT01001221", "title": "Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neoplasms, Malignant" ], "interventions": [ { "name": "cabazitaxel", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2009-11", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2013-09-11", "last_synced_at": "2026-10-06T17:09:40.220Z", "location_count": 4, "location_summary": "Detroit, Michigan • Cincinnati, Ohio • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01001221" }, { "nct_id": "NCT06460961", "title": "A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm Metastasis" ], "interventions": [ { "name": "MK-6837", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Rescue Medications", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2024-07-14", "completion_date": "2026-07-29", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-06T17:09:40.220Z", "location_count": 3, "location_summary": "Morristown, New Jersey • Portland, Oregon • San Antonio, Texas", "locations": [ { "city": "Morristown", "state": "New Jersey" }, { "city": "Portland", "state": "Oregon" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06460961" }, { "nct_id": "NCT02655458", "title": "Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "autologous PBMC reconstitution", "type": "OTHER" }, { "name": "ASCT", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hearn Jay Cho", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2016-01", "completion_date": "2017-07-13", "has_results": false, "last_update_posted_date": "2017-08-18", "last_synced_at": "2026-10-06T17:09:40.220Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02655458" }, { "nct_id": "NCT04840615", "title": "Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mesothelioma" ], "interventions": [ { "name": "LMB-100", "type": "BIOLOGICAL" }, { "name": "ipilimumab", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Famotidine", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "FDG-PET", "type": "DIAGNOSTIC_TEST" }, { "name": "CT CAP", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "ECG", "type": "DIAGNOSTIC_TEST" }, { "name": "Echocardiogram", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 2, "start_date": "2021-06-11", "completion_date": "2022-01-12", "has_results": true, "last_update_posted_date": "2024-02-02", "last_synced_at": "2026-10-06T17:09:40.220Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04840615" }, { "nct_id": "NCT06393374", "title": "Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Triple-Negative Breast Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Sacituzumab tirumotecan", "type": "BIOLOGICAL" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1530, "start_date": "2024-06-24", "completion_date": "2037-12-14", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-06T17:09:40.220Z", "location_count": 93, "location_summary": "Mobile, Alabama • Chandler, Arizona • Fountain Valley, California + 78 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Alamitos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06393374" } ] }